Factor XI (FXI) deficiency is a rare autosomal bleeding disease associated with genetic defects in the FXI gene. It is a heterogeneous disorder with variable tendency in bleeding and variable causative FXI gene mutations. It is characterized as a cross-reacting material-negative (CRMÀ) FXI deficiency due to decreased FXI levels or cross-reacting material-positive (CRMþ) FXI deficiency due to impaired FXI function. Increasing number of mutations has been reported in FXI mutation database, and most of the mutations are affecting serine protease (SP) domain of the protein. Functional characterization for the mutations helps to better understand the molecular basis of FXI deficiency. Prevalence of the disease is higher in certain populations such as Ashkenazi Jews. The purpose of this review is to give an overview of the molecular basis of congenital FXI deficiency.
Introduction
Factor XI (FXI) is a homodimeric plasma glycoprotein that is essential for the hemostasis. It circulates as a zymogen of the serine protease (SP)-activated FXI (FXIa) in noncovalent interaction with cofactor high-molecular-weight kininogen (HK). Factor XIa is required for the activation of FIX to maintain thrombin production during coagulation process at the site of vascular injury. 1, 2 Congenital factor XI deficiency is a rare bleeding disorder. It is characterized by bleedings after injury or surgery with decreased FXI activity, normal prothrombin time (PT), and platelet count. It is common to Ashkenazi Jewish population with a heterozygote frequency of 8% (FXI:C 15-70 IU/dL). 3 FXI:C plasma level is 70 to 150 IU/dL in normal populations. Factor XI deficiency is inherited as an autosomal trait. Bleeding due to FXI deficiency is variable, and it does not correlate with the plasma FXI level. 4, 5 Spontaneous bleedings are rare even in severely affected patients and they may not bleed significantly after surgical operations. However, bleedings after surgery or trauma in tissues such as the mouth, nose, and genitourinary tracts with high fibrinolytic activity can be life threatening. [6] [7] [8] The molecular pathology of the FXI deficiency has been associated with the mutations in the FXI gene encoding FXI. More than 190 different mutations have been described in the FXI mutation databases (http://www.factorxi.com/; http:// www.wienkav.at/kav/factorxi/Faktor_XI_Suche.asp).
FXI Gene and FXI Protein
The gene encoding FXI has been localized to chromosome 4 (4q35). It is composed of 15 exons and 14 introns (A to N) and spans a 23-kb region. 9, 10 The gene is mainly expressed by the liver cells, and liver-specific expression is regulated by the transcription factor hepatocyte nuclear factor 4 (HNF4)-a. 11 À273 C/G and À403 G/T changes are the 2 common polymorphisms found in the promoter region, and the À273 (C/ G) polymorphism affects the transcription factor binding in vitro. 12 Factor XI messenger RNA (mRNA) is also detected in platelets, blood mononuclear cells, granulocytes, pancreas, and kidney. [13] [14] [15] [16] Exon 1 encodes for the promoter region, exon 2 encodes for the 18 amino acid long-signal peptide that is cleaved during FXI biosynthesis, and exons 3 to 15 encode for the 607 amino acid long mature protein. 9 Factor XI is synthesized as homodimeric glycoprotein (160 kDa). Studies have shown that the dimeric structure of FXI is essential for the efficient secretion and function. 17 The FXI monomer (80 kDa) is made up of 4 N-terminal apple domains (A1, A2, A3, and A4) and a C-terminal trypsin like catalytic domain ( Figure 1 ). Apple domains are about 90 amino acids long, and the catalytic domain is 238 amino acids long. Prekallikrein (PK) and FXI are the 2 coagulation factors having the similar apple domain structure. The apple domains exhibit homology to each other and to the apple domains in PK. [18] [19] [20] Each of the apple domains has a loop structure maintained by 3 disulfide bonds, and they are involved in the interactions with other molecules. A1 provides the site for the prothrombin, thrombin, and HK binding; A2 and A3 are responsible for FIX binding; A3 is also responsible for platelet and heparin binding; A4 is essential for the dimerization and FXII binding. Dimers are formed with a disulphide bond between residue C321 and noncovalent interactions in the A4 domain of each FXI monomer. [21] [22] [23] [24] [25] [26] [27] In vitro analysis of the specific amino acid residues within the A4 domain demonstrated that Leu284, Ile290, and Tyr329 residues are essential for the noncovalent bond formation during dimerization. 28 Factor XI is 5% glycosylated, and it contains Asn residues at positions 72, 108, 335, 432, and 473 that are the 5 potential N-linked glycosylation sites. Three of these glycosylation sites (Asn 108, Asn 432, and Asn 473) are conserved in PK. 18, 19, 29 Factor XI is the only coagulation SP that circulates as a dimer. Factor XI is activated by thrombin produced by the extrinsic pathway during coagulation process or by FXIIa and FXIa by the proteolytic cleavage of the peptide bond between Arg369 and Ile370. 30 The interaction of FXI with HK facilitates binding to the surface of activated platelets, which causes efficient activation of FXI. 31 Activated FXI is composed of 2 N-terminal heavy chains (48 KDa) and 2 C-terminal light chains (32 kDa). The heavy chain contains the Apple domains and the light chain contains the catalytic domain with the catalytic triad (His413, Asp462, Ser557), which is the characteristic feature of SPs. Dimeric structure of FXIa is maintained by 3 disulfide bonds: the 2 connecting heavy and light chains in the monomers and the 1 connecting the monomers. 29, 32 In vitro studies revealed that FXIa activity is regulated by the Kunitz-type inhibitor protease nexin 2 that is produced in platelets. 33 Factor XIa activates FIX, and this activation contributes to the thrombin production in the coagulation process to maintain hemostasis. Thrombin generation results in the feedback activation of FXI and protection of the clot from fibrinolysis in the presence of FXI. 34 Studies have shown that FXI has antifibrinolytic activity due to thrombin activation of thrombin-activatable fibrinolysis inhibitor (TAFI), which inhibits plasmin production by tissue plasminogen activator and in turn prevents fibrinolysis. 35 Absence of FXI antifibrinolytic activity in the patients with FXI deficiency provides the mechanism for the variable bleeding in tissues with high local fibrinolytic activity such as urinary tract, nose, and oral cavity. High morbidity rate in FXI-deficient Jewish females due to obstetric and gynecologic bleeding also demonstrates the functional importance of FXI antifibrinolytic activity in the coagulation process. 6, 7, 36 Moreover, it has been indicated that increased FXI levels are a risk factor for venous thrombosis with a relative risk of 2.2. 37 However, FXI deficiency can provide protection against thrombosis. Wang et al 38 demonstrated that FXI deficiency provides protection against FeCl 3 -induced vena cava thrombosis in mice. Investigation of the incidence of ischemic stroke in an epidemiologic study with 115 severely affected FXI deficiency patients in Israeli population revealed a decreased incidence of ischemic stroke. 39 This observation suggested that severe FXI deficiency may be protective against ischemic stroke. However, comparison of the incidence of the acute myocardial infarction (AMI) in the normal individuals and patients with severe FXI deficiency in Israeli population disclosed that FXI deficiency does not provide protection against AMI. 40 
Molecular Pathogenesis of Inherited FXI Deficiency
Congenital FXI deficiency is a rare bleeding disorder observed with a frequency of 1:1 000 000 worldwide. 41 However, it is prevalent in some ethnic groups like Jews of Ashkenazi or Iraqi origin with a heterozygote frequency of 8% or 3.3%, respectively. 3 It is first described by Rosenthal in 1953 by decreased FXI activity. Factor XI deficiency has been associated with the mutations within the FXI gene and most of the mutations are associated with CRM-phenotype, which is the proportional decrease in the FXI:Ag and FX:C levels. Fewer FXI mutations are associated with the CRMþ FXI phenotype, which is due to the presence of dysfunctional FXI circulating in the plasma with normal FXI:Ag levels. The reason is not clear, but there is no direct relationship between bleeding tendency and plasma FXI levels. Both heterozygotes and homozygotes are at risk of bleeding, and heterozygotes may have FXI plasma levels at the lower end of the normal range. Patients are diagnosed as severely affected when the activity of FXI is less than 15 U/dL. Severely affected patients do not have spontaneous bleedings; however, bleedings after a surgery or trauma in tissues with high fibrinolytic activity might be life threatening. 6, 7 Besides, severely affected patients are at risk of developing inhibitors to FXI. For example, inhibitor development was observed in homozygotes for Glu117Stop mutation who received plasma replacement therapy or injection of Rh immunoglobulin. 42, 43 Patients with the similar FXI levels may bleed differently or bleeding tendency may change over time in the same patient. Besides, additional deficiencies for blood coagulation factors, such as von Willebrand factor, may affect bleeding tendency. 44 Factor XI deficiency has been associated with a wide range of mutations including missense, nonsense, splice site, insertion, and deletion mutations within the FXI gene. Missense mutations account for the 53% of the mutations identified in the FXI gene. The largest number of mutation The substitution is associated with functional abnormality due to a failure in the FXI activation 55 9 c. 901T>C Phe283Leu A4 Decreased FXI secretion; FXI:Ag 0.017 + 0.01 U/mL Mutation interferes with the dimer formation, causing the accumulation of FXI monomers in the cell 21 9 c. 959T>C Leu302Pro A4 Decreased FXI secretion Mutation impairs the FIX secretion 56 9 c. 965C>T Thr304Ile A4 Decreased FXI secretion Mutation impairs the FIX secretion 56 9 c. 1021G>A Glu323Lys A4 Decreased FXI secretion Mutation impairs the FIX secretion 56 is identified within the SP of FXI with 32% frequency (http://www.factorxi.org/). FXI gene mutations were first described in the Ashkenazi Jewish population. There are 4 mutations (type I to type IV) specific to this population. Type I (G to A substitution in the donor splice site in intron N) and type IV (14 base deletion in intron N) mutations are the splicing mutations. Type II is a nonsense mutation (Glu117Stop) and type III is a missense mutation (Phe283-Leu). Type II and type III are the most commonly seen of the 4 Jewish mutations (95% of the cases). 45, 46 Glu117Stop is also detected in other populations. In addition to the mutations specific to Ashkenazi Jewish population, there are other FXI variants found with a relatively high frequency in different populations such as the Cys38Arg mutation in French Basques, 47 the Cys88Stop mutation in the French people from Nantes 48 and the Cys128Stop mutation in the United Kingdom. 49 Functional characterization is done for small number of mutations, and the list of the FXI gene mutations that had been characterized by in vitro expression studies is given in Table 1 (FXI:Ag and FXI:C values for the recombinant mutant constructs are given wherever available). Cross-reacting material-negative FXI deficiency is classified into 3 groups according to the mechanistic effect of the FXI gene mutation. The first group is caused by the mutations such as Glu117X, Ala91Thr that affect protein synthesis and cause selective degradation of the mutant transcript by nonsense mediated decay. 32, 52 The second group is caused by the mutations within A4 domain, such as Phe283Leu, that inhibit the dimer formation and result in the intracellular retention of the FXI monomers. 17, 21 The third group is caused by mutations such as Gly400Val, Trp596Ser, Ser225Phe, and Cys398Tyr that cause nonsecretable homodimers and also probably affecting secretion of heterodimers formed with the wild type FXI allele, thereby resulting in dominant phenotype. 53, 54 However, there are FXI mutations (Cys58Tyr, Tyr427Cys, Cys527Tyr, Val20Ala, and Glu297Lys) that reduce the secretion of the mutant protein from the cell without affecting the dimerization of the protein possibly by causing misfolding of the protein. 51 
Conclusion
Factor XI deficiency is a rare congenital bleeding disease. It is heterogeneous in clinical presentation and in genetic causality. Factor XI deficiency can be CRM-or less frequent form CRMþ. Various types of mutations have been identified throughout the FXI gene associated with CRMþ or CRM-FXI deficiency and most of them are missense mutations. Factor XI deficiency represents ethnic heterogeneity with the higher prevalence of certain mutations in specific populations such as high prevalence of Glu117Stop mutation in the Ashkenazi Jewish population. Although molecular pathology of CRM-FXI deficiency is well defined, molecular mechanism of CRMþ FXI deficiency is poorly identified. In vitro expression studies of large number of mutations causing CRM-FXI deficiency revealed that the molecular mechanism of FXI deficiency is heterogeneous. Mutations can cause selective degradation of the mutant transcript, intracellular retention of monomers, intracellular retention of homodimers as well as heterodimers. Mutations can also impair the dimer formation or decrease the secretion of the mutant protein without affecting the dimer formation. 51 15 c. 1718G>A Gly555Glu SP Reduced FXI:C activity; FXI:C <1% Reduced FIX activation and resistance to antithrombin inhibition possibly by altering the electrostatic charge around the active site 59 15 c. 1760G>C Trp569Ser SP Poor FXI secretion; FXI:Ag 0.5% + 0.1% Mutation has dominant-negative effect 53 15 c. 1778C>T Thr575Met SP Reduced FXI:C activity; FXI:Ag 470 ng/mL and FXI:C 3.5 U/dL Mutation impairs FIX activation activity 50 NOTES: FXI ¼ factor XI; SP ¼ serine protease; NMD ¼ nonsense mediated decay.
